---
title: "Royalty Pharma (RPRX) Gets a Buy from TD Cowen"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285498617.md"
description: "TD Cowen analyst Michael Nedelcovych has maintained a Buy rating on Royalty Pharma (RPRX) with a price target of $50.00. The stock closed at $50.72. The analyst has an average return of -4.2% and a 41.67% success rate, focusing on the Healthcare sector. The consensus on Royalty Pharma is a Strong Buy, with an average price target of $54.17."
datetime: "2026-05-07T06:36:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285498617.md)
  - [en](https://longbridge.com/en/news/285498617.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285498617.md)
---

# Royalty Pharma (RPRX) Gets a Buy from TD Cowen

TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Royalty Pharma yesterday and set a price target of $50.00. The company’s shares closed yesterday at $50.72.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Nedelcovych is an analyst with an average return of \-4.2% and a 41.67% success rate. Nedelcovych covers the Healthcare sector, focusing on stocks such as Royalty Pharma, Bausch Health Companies, and Novo Nordisk.

Currently, the analyst consensus on Royalty Pharma is a Strong Buy with an average price target of $54.17.

### Related Stocks

- [RPRX.US](https://longbridge.com/en/quote/RPRX.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BHC.US](https://longbridge.com/en/quote/BHC.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)